An Antimicrobial Blue Light Prototype Device Controls Infected Wounds in a Preclinical Porcine Model.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 39535214.
- Also identified by DOI 10.1093/infdis/jiae548 and PMC identifier 11911787.
- Licence recorded as CC BY.
- The licence permits redistribution, so the abstract is shown in full and the full text is available from the publisher.
Abstract
We developed a translational prototype antimicrobial blue light (ABL) device for treating skin wounds with ABL. Partial-thickness surgical wounds were created in live swine (an animal whose skin is considered the most like human skin), then heavily contaminated and left untreated for 24 hours with methicillin-resistant Staphylococcus aureus (MRSA). ABL treatment stabilized and reduced MRSA infection by greater than 4 orders of magnitude (>99.99%; P < .0001) compared with untreated wounds in the same animal, after only 2 daily treatments. These data support further development of such devices for controlling infection in skin wounds. ABL, with or without concomitant administration of negative pressure, antimicrobials, or photosensitizers, could play an important role in modern wound care by reducing the amount, duration, and cost of antibiotics needed, helping reduce antimicrobial resistance. No such device for treating human cutaneous wounds currently exists. This deserves further development and study.
Medical subject headings
- Methicillin-Resistant Staphylococcus aureus
- Wound Infection
- Staphylococcal Infections
- Light
- Phototherapy